We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Epigenomics Collaborates with Myriad Genetics to Discover DNA Methylation Biomarkers

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Epigenomics Collaborates with Myriad Genetics to Discover DNA Methylation Biomarkers"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Epigenomics AG has entered into R&D collaboration with Myriad Genetics, Inc. to identify and analyze DNA methylation biomarkers that may predict patients’ response to an undisclosed marketed oncology drug.

Under the agreement, Epigenomics will use its proprietary Differential Methylation Hybridization (DMH) microarray platform to perform genome-wide DNA methylation profiling on samples provided by Myriad and compare these profiles to identify DNA methylation biomarkers associated with sensitivity and resistance to the drug.

Epigenomics will also apply its OncoSign™ approach that is offered in collaboration with its partner CellTrend GmbH (Luckenwalde, Germany) for fast track identification of DNA methylation biomarkers for the drug in an established panel of human tumor cell lines. Financial details were not disclosed.

“We are excited to bring our DMH technology for the discovery of predictive biomarkers to Myriad Genetics, a company well known for its expertise in genetic marker tests,” noted Christina Dahlstroem, Ph.D., Epigenomics’ Senior Vice President Clinical Solutions.

“This collaboration highlights the importance of DNA methylation profiling in the search for biomarkers that will improve therapeutic choices in oncology,” Dahlstroem added.